You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,629,343


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,629,343
Title: N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents
Abstract:Novel N-(mercaptoacyl)peptidyl compounds are useful as inhibitors of matrix metalloendoproteinases which degrade major components of articular cartilage and basement membranes causing degenerative diseases such as arthritis, periodontal disease, corneal ulceration, are described. For example, N-(2-thiomethyl-4-phenyl-butanoyl)-L-leucinamide was prepared and its inhibitory activity against stromelysin was tested in vitro.
Inventor(s): Hagmann; William (Westfield, NJ), Kopka; Ihor (Millburn, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:08/392,730
Patent Claims:1. A compound of formula I ##STR8## wherein R.sub.1 is hydrogen, acetyl or benzoyl, R.sub.2 is hydrogen or methyl,

R.sub.3 is 2-phenylethyl or 2-[4-(C.sub.1-3 alkyl)phenyl]ethyl, ##STR9## is an L-amino acid, ##STR10## is a residue of .beta.-alanine, L-alanine, glycine and aniline.

2. A compound according to claim 1 selected from the group consisting of:

(a) N-(2-thiomethyl-4-phenylbutanoyl)-(L)-leucinamide;

(b) N-(2-thiomethyl-4-phenylbutanoyl)-(L)-leucine, N-penylamide;

(c) N-(2-thiomethyl-4-phenylbutanoyl)-(L)-leucine, N-benzylamide;

(d) N-(2-thiomethyl-4-phenylbutanoyl)-(L)-leucine, N-(2-phenylethyl)amide;

(e) N-(2-thiomethyl-4-phenylbutanoyl)-(L)-phenylalaninamide;

(f) N-(2-thiomethyl -4-phenylbutanoyl)-(L)-phenylalanine, N-phenylamide;

(g) N-(2-thiomethyl-4-phenylbutanoyl)-(L)-phenylalanine, N-benzylamide;

(h) N-(2-thiomethyl-4-phenylbutanoyl)-(L)-phenylalanine-b-alanine.

3. A composition useful for inhibiting the lytic activity of matrix metalloendoproteinases comprising a lysis inhibiting amount of a compound of claim 1 in admixture with a pharmaceutically acceptable carrier.

4. A composition in unit dose form useful for inhibiting the lytic activity of matrix metalloendoproteinases comprising from about 1 mg to about 500 mg of the compound of claim 1 and a pharmaceutically acceptable carrier.

5. A compound of formula I ##STR11## or a pharmaceutically acceptable salt thereof wherein: R.sub.1 is H, C.sub.1-6 alkylmercapto, C.sub.2-6 alkanoyl, C.sub.7-11 aroyl:

R.sub.2 is H, C.sub.1-6 alkyl, substituted C.sub.1-6 alkyl wherein the substituent is carboxyl, carboxamido, hydroxy, sulfonamide;

R.sub.3 is C.sub.6-10 arylC.sub.2-3 alkyl or C.sub.6-10 aryl substituted C.sub.2-3 alkyl wherein the substituent is C.sub.1-3 alkyl or hydroxy, and wherein the aryl group is selected from the group consisting of:

(1) phenyl,

(2) naphthyl,

(3) pyridyl,

(4) pyrryl,

(5) furyl,

(6) thienyl,

(7) isothiazolyl,

(8) imidazolyl,

(9) benzimidazolyl,

(10) tetrazolyl,

(11) pyrazinyl,

(12) pyrimidyl,

(13) quinolyl,

(14) isoquinolyl,

(15) benzofuryl,

(16) isobenzofuryl,

(17) benzothienyl,

(18) pyrazolyl,

(19) indolyl,

(20) isoindolyl,

(21) purinyl,

(22) carbazolyl,

(23) isoxazolyl,

(24) thiazolyl,

(25) oxazolyl

(26) benzthiazolyl, and

(27) benzoxazolyl,

and mono and di-substituted C.sub.6-10 aryl as defined above in items (1) to (27) wherein the substituents are independently selected from C.sub.1-6 alkyl, C.sub.1-6 alkaloxy, halo, hydroxy, amino, C.sub.1-6 alkylamino, aminoC.sub.1-6 alkyl, carboxyl, C.sub.1-6 alkyl, and C.sub.1-6 alkylcarbonyl;

R.sub.e and R.sub.f are individually selected from:

(a) hydrogen

(b) C.sub.1-6 alkyl,

(c) mercapto C.sub.1-6 alkyl,

(d) hydroxy C.sub.1-6 alkyl,

(e) carboxy C.sub.1-6 alkyl,

(f) amino substituted C.sub.2-6 alkyl,

(g) aminocarbonyl C.sub.1-6 alkyl,

(h) mono- or di-C.sub.1-6 alkylamino C.sub.2-6 alkyl,

(i) guanidino C.sub.2-6 alkyl,

(j) substituted phenylC.sub.1-6 alkyl, wherein the substituent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

(k) substituted indolylC.sub.1-6 alkyl, wherein the substituent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

(l) substituted imidazolylC.sub.2-6 alkyl wherein the substituent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

(m) substituted pyridylC.sub.1-6 alkyl wherein the substituent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy,

(n) substituted pyridylaminoC.sub.1-6 alkyl wherein the substituent is hydrogen, hydroxy, carboxy, C.sub.1-4 alkyl, or C.sub.1-4 alkyloxy;

R.sub.5 is selected from the group consisting of:

(a) H,

(b) C.sub.1-10 alkyl,

R.sub.6 is selected from the group consisting of:

(a) carboxy C.sub.1-2 alkyl, and

(b) C.sub.6-10 aryl wherein the aryl group is selected from the group consisting of:

(1) phenyl,

(2) naphthyl,

(3) pyridyl,

(4) pyrryl,

(5) furyl,

(6) thienyl,

(7) isothiazolyl,

(8) imidazolyl,

(9) benzimidazolyl,

(10) tetrazolyl,

(11) pyrazinyl,

(12) pyrimidyl,

(13) quinolyl,

(14) isoquinolyl,

(15) benzofuryl,

(16) isobenzofuryl,

(17) benzothienyl,

(18) pyrazolyl,

(19) indolyl,

(20) isoindolyl,

(21) purinyl,

(22) carbazolyl,

(23) isoxazolyl,

(24) benzthiazolyl,

(25) benzoxazolyl,

(26) thiazolyl, and

(27) oxazolyl.

6. A compound which is N-(2-thiomethyl-4-phenylbutanoyl)-(L)-leucine, N-benzylamide, or a pharmaceutical acceptable salt thereof.

7. A composition useful for inhibiting the lytic activity of matrix metalloendoproteinases comprising a lysis inhibiting amount of a compound of claim 6 in admixture with a pharmaceutically acceptable carrier.

8. A method for inhibiting the lytic activity of metalloendoproteinases comprising administering to a subject suffering from matrix metalloendoproteinase mediated disease, an inhibitory amount of the compound of claim 1.

9. A method according to claim 8 in which the metalloendoproteinases is stromelysin.

10. A method according to claim 8 in which the metalloendoproteinase is collagenase.

11. A method according to claim 8 in which the metalloendoproteinase is gelatinase.

12. A method for inhibiting the activity of stromelysin comprising administering to a patent suffering from stromelysin mediated disease, a therapeutic amount of the compound of claim 1.

13. A method according to claim 12 wherein the stromelysin inhibitor is administered in an amount of from about 0.01 to 50 mg of the compound per kilogram of body weight per day.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.